Spotlight
November 3, 2020
Lannett Launches Authorized Generic of Tirosint®
Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP). Lannett entered into an exclusive U.S. distribution agreement with IBSA Institut Biochimique SA, a global pharmaceutical company headquartered in Switzerland. Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits.
Tirosint® is a registered trademark of IBSA Institut Biochimique SA.
